Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BND-22 |
Synonyms | |
Therapy Description |
BND-22 is an anti-ILT2 monoclonal antibody that blocks ILT2 from interacting with HLA-G, potentially leading to immunosuppressive effects and subsequent anti-tumor activity, including increased macrophage activity and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3266). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BND-22 | BND22|BND 22|SAR444881 | BND-22 is an anti-ILT2 monoclonal antibody that blocks ILT2 from interacting with HLA-G, potentially leading to immunosuppressive effects and subsequent anti-tumor activity, including increased macrophage activity and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3266). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |